首页> 外文期刊>Stem cells international >Clinical Application of Human Induced Pluripotent Stem Cell-Derived Organoids as an Alternative to Organ Transplantation
【24h】

Clinical Application of Human Induced Pluripotent Stem Cell-Derived Organoids as an Alternative to Organ Transplantation

机译:人诱导多能干细胞衍生有机体作为器官移植的替代方法

获取原文
获取外文期刊封面目录资料

摘要

Transplantation is essential and crucial for individuals suffering from end-stage organ failure diseases. However, there are still many challenges regarding these procedures, such as high rates of organ rejection, shortage of organ donors, and long waiting lines. Thus, investments and efforts to develop laboratory-grown organs have increased over the past years, and with the recent progress in regenerative medicine, growing organs in vitro might be a reality within the next decades. One of the many different strategies to address this issue relies on organoid technology, a miniaturized and simplified version of an organ. Here, we address recent progress on organoid research, focusing on transplantation of intestine, retina, kidney, liver, pancreas, brain, lung, and heart organoids. Also, we discuss the main outcomes after organoid transplantation, common challenges faced by these promising regenerative medicine approaches, and future perspectives on the field.
机译:移植对患有终级器官衰竭疾病的个体至关重要,至关重要。 然而,这些程序仍存在许多挑战,例如机器人拒绝,器官捐赠短缺以及漫长的等候线。 因此,发展实验室生长的器官的投资和努力在过去几年增加,并且随着再生医学的进展,体外的生长器官可能是未来几十年内的现实。 解决此问题的许多不同策略之一依赖于有机技术,一个小型化和简化的器官版本。 在这里,我们解决了有机体研究的最近进展,重点是肠,视网膜,肾,肝,胰腺,脑,肺和心脏器材的移植。 此外,我们讨论了有机体移植后的主要结果,这些有前途的再生医学方法以及对该领域的未来观点面临的共同挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号